JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 138 filers reported holding JUNO THERAPEUTICS INC in Q3 2015. The put-call ratio across all filers is 2.12 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2016 | $41,000 | -22.6% | 1,370 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $53,000 | +960.0% | 1,370 | +930.1% | 0.00% | – |
| Q1 2016 | $5,000 | -16.7% | 133 | 0.0% | 0.00% | – |
| Q4 2015 | $6,000 | -40.0% | 133 | -46.8% | 0.00% | – |
| Q3 2015 | $10,000 | -23.1% | 250 | 0.0% | 0.00% | – |
| Q2 2015 | $13,000 | – | 250 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Biomark Capital Management Co. LLC | 2,168,601 | $65,080,000 | 86.12% |
| Crestline Management, LP | 17,348,799 | $520,637,000 | 66.02% |
| Omega Fund Management, LLC | 1,229,512 | $36,898,000 | 28.17% |
| SIB LLC | 100,000 | $3,001,000 | 2.42% |
| Clarius Group, LLC | 117,896 | $3,538,000 | 1.65% |
| BB BIOTECH AG | 1,405,000 | $42,164,000 | 1.48% |
| Duquesne Family Office | 493,000 | $14,795,000 | 1.31% |
| First Washington CORP | 65,320 | $1,960,000 | 1.10% |
| PFM Health Sciences, LP | 1,124,285 | $33,740,000 | 0.99% |
| Partner Investment Management, L.P. | 18,376 | $551,000 | 0.82% |